Refractory angina refers to chronic chest pain or angina that occurs even after the optimal medication and coronary revascularization procedures. It occurs due to inadequate oxygen and blood supply to the heart muscles. Some of the key treatments available for refractory angina includes enhanced external counterpulsation (EECP), spinal cord stimulation (SCS) therapy, and transmyocardial laser revascularization (TMR). These relieve symptoms by improving blood flow to the heart. The global refractory angina treatment market is witnessing growth due to increasing prevalence of cardiovascular diseases. The rising geriatric population is also leading to higher incidence of chronic diseases. Additionally, favorable reimbursement policies and product approvals are encouraging adoption of advanced technologies in many countries.
The Global Refractory Angina Treatment Market is estimated to be valued at USD 200.1 Mn in 2024 and is expected to reach USD 312.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Key Takeaways
Key players operating in the Refractory Angina Treatment Market are Abbott Laboratories, Sanofi, MicroPort Scientific Corporation, and others. These companies are focusing on increasing awareness about advanced treatment options and improving their penetration in developing regions.
The growing demand for minimally invasive procedures is a major factor boosting market growth. Refractory angina can significantly reduce the quality of life of patients experiencing frequent chest pain. This is prompting them to opt for advanced interventions at early stages. Moreover, growing geriatric population suffering from multiple chronic conditions augment the demand.
The market is witnessing an increased focus on expanding operations across emerging countries. This is due to rising healthcare expenditure, access to insurance, and growing incidence of cardiovascular diseases. Major players are forming strategic alliances with regional companies and enhancing their distribution networks in Asia Pacific and Latin America.
Market drivers
Increasing prevalence of cardiovascular diseases is the primary factor driving the refractory angina treatment market. According to the World Health Organization (WHO), cardiovascular diseases cause around 18 million deaths annually across the globe. Unhealthy dietary habits, lack of exercise, rising stress levels, tobacco use, and obesity are increasing the risk of heart attacks and strokes. This is leading to a rise in treatment-resistant chest pain cases. The growing awareness about available minimally invasive treatment options is also boosting the adoption rates. Favorable reimbursement scenario in developed countries and government initiatives to enhance screening in emerging nations will continue fueling the market growth over the forecast period.
The current geopolitical situation is having a notable impact on the growth of the refractory angina treatment market. Rising political tensions and conflicts around the world have disrupted global supply chains and trade relations. This has restricted the movement of raw materials and finished drugs across borders, hampering the production and distribution of refractory angina treatments. Additionally, economic uncertainties caused by geopolitical issues have weakened consumer spending on non-essential medical therapies in several markets.
To mitigate these challenges, companies in the refractory angina treatment market need to diversify their manufacturing and sourcing networks globally. Establishing facilities and partnerships in politically stable regions can help mitigate supply risks. These organizations also need to focus on cost control initiatives to make therapies more affordable for patients from diverse economic backgrounds. Adopting advanced digital technologies for remote patient monitoring and care can further boost access to treatment in locations impacted by geopolitical instability or conflicts. Collaborating with local healthcare entities and philanthropic organizations can aid supply and delivery of essential medications in such areas as well.
The North American market holds the largest share of the overall refractory angina treatment market currently, in terms of value. This can be largely attributed to the region's well-established healthcare infrastructure and robust reimbursement framework. With an increasing prevalence of cardiovascular diseases as well as a sizable patient pool undergoing treatment in the U.S. and copyright, the demand for refractory angina medications remains consistently high across North America.
The Asia Pacific region is poised to be the fastest growing market for refractory angina treatment globally over the coming years. Factors such as the rising healthcare expenditure of developing Asian nations, growing awareness about chronic conditions, and expanding medical capabilities are fueling the demand. Burgeoning senior populations in China and India that are vulnerable to heart diseases also present considerable growth opportunities. Additionally, increasing collaborations between local pharmaceutical firms and international players are enhancing the accessibility of innovative angina therapies across Asia Pacific.
Get More Insights on - Refractory Angina Treatment Market
Author Bio:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)